Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Aveanna Healthcare Holdings Inc. (AVAH) SEC Filings & Earnings Calls

EquiReason read 23 Aveanna Healthcare Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees..

Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason

AVAHAveanna Healthcare Holdings Inc.Follow AVAH — free
Medical Care Facilities · Healthcare
—
Price chart with a free account
Market cap
2.9B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
5 Nov, in 12 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

2 Oct 20268-K · 5.02Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees.open

Risks flagged

Loss of independent director with committee roles may reduce board oversight temporarily.

“Mr. Rodgers was an independent director, serving on both the Audit Committee and the Compensation Committee.” · word for word
Read the original on SEC EDGAR ↗
24 Aug 20268-K · 8.01Aveanna Healthcare secondary offering of 15M shares at $11.75 by selling stockholders; company received no proceeds; potential overhang from additional 2.25M share option.open

Figures in the filing · each found in the filing text

Secondary Offering Shares · Q3-202615,000,000
Public Offering Price · Q3-2026$11.75
Over-Allotment Option Shares · Q3-20262,250,000

Risks flagged

Insider selling via secondary offering signals potential lack of confidence or need for liquidity by major shareholders, increasing dilution risk for existing shareholders.

“Selling stockholders include affiliates of J.H. Whitney Equity Partners VII, LLC and certain current and former directors and officers.”
Read the original on SEC EDGAR ↗
13 Aug 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportSEC ↗
13 Aug 20268-K · 2.02, 7.01Revenue $670M (+14% y/y); Net Income $40M (+49% y/y); Adjusted EBITDA $95M (+8% y/y); Guidance: Revenue >$2.68B (from $2.63-2.65B); Adj. EBITDA >$365M (from $338-342M)earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$671M+14% y/y
Net Income · Q2-2026$40M+49% y/y
Adjusted EBITDA · Q2-2026$95M+8% y/y
Gross Margin · Q2-2026$219M+4% y/y
Cash and Cash Equivalents · Q2-2026$97M
Free Cash Flow · H1-2026$75M
Total Indebtedness · Q2-2026$1.48B
Net Income per Diluted Share · Q2-2026$0.18+39% y/y
Adjusted Net Income per Diluted Share · Q2-2026$0.22+22% y/y

Guidance

Revenue >$2.68B (from $2.63-2.65B); Adj. EBITDA >$365M (from $338-342M)

Full-year 2026 guidance raised significantly: Revenue >$2.68B (from $2.63-2.65B), Adj. EBITDA >$365M (from $338-342M), reflecting strong H1 performance and confidence in outlook.

Risks flagged

Gross margin rate declined from 35.8% to 32.6% due to mix shift or cost pressures.

“Gross margin was 32.6% of revenue vs 35.8% in prior year period.”

High leverage with total indebtedness of $1.48B; interest rate exposure partially hedged.

“Total indebtedness $1,483.4M; interest rate caps on $1.4B notional.”
Read the original on SEC EDGAR ↗
13 Aug 202610-QAveanna Healthcare reported Q2 2026 revenue growth of 13.7% YoY, but gross margin declined 3.2pp due to labor cost inflation; net income increased 49.1% YoY driven by lower interest expense.earningsopen

Figures in the filing · each found in the filing text

Revenue · Q2-2026$670M+14% y/y
Gross margin · Q2-202632.6%
Adjusted EBITDA · Q2-2026$95M+8% y/y
Net income · Q2-2026$40M+49% y/y
Operating cash flow · H1-2026$85M+99% y/y
PDS Hours · PDS · Q2-202612,413,000+12% y/y
PDS Revenue Rate · PDS · Q2-2026$44.62+1% y/y
PDS Cost of Revenue Rate · PDS · Q2-2026$31.74+7% y/y
PDS Spread Rate · PDS · Q2-2026$12.88-10% y/y
HHH Total Episodes · HHH · Q2-202614,700+19% y/y

Risks flagged

Gross margin compression from labor cost inflation

“The 7.8% increase in cost of revenue rate primarily resulted from higher caregiver labor costs, including the pass-through of reimbursement rate increases and higher general and professional liability reserves in the second quarter of 2026.” · word for word

Integration risk from acquisitions

“Acquisition-related costs were $4.4 million for the three-month period ended July 4, 2026, as compared to $3.4 million for the three-month period ended June 28, 2025.” · word for word

Interest rate derivative exposure

“We realized a $5.4 million decrease in non-cash valuation losses associated with interest rate derivatives resulting from changes in market expectations of future interest rates as of the comparable quarter-end valuation date, partially offset by a $2.4 million decrease in net settlements with interest rate derivative counterparties as interest rates decreas”
Read the original on SEC EDGAR ↗
7 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Loss of independent director with clinical quality expertise; minimal near-term risk.

“Resignation of Chair of Clinical Quality Committee; no operational disagreement.”
Read the original on SEC EDGAR ↗
2 Jun 20268-K · 8.01Acquisition cost $176Mopen

Figures in the filing · each found in the filing text

acquisition cost · Q2-2026$176M

Guidance

Guidance updated to reflect acquisition contribution, implying revenue growth but no margin detail.

Risks flagged

Integration risk from acquisition; potential for higher leverage or operational disruption.

“acquisition funded with cash on hand; integration of Family First operations may strain resources”
Read the original on SEC EDGAR ↗
28 May 20268-K · 8.012026 Term Loans $1.32B; 2026 Refinancing Revolving Credit Facility $250M; interest rate margin reduction 0.5open

Figures in the filing · each found in the filing text

2026 Term Loans · 2026-05-26$1.32B
2026 Refinancing Revolving Credit Facility · 2026-05-26$250M
interest rate margin reduction · 2026-05-260.5%

Risks flagged

Debt repricing reduces interest expense, but leverage remains high.

“repricing of the facilities” · word for word
Read the original on SEC EDGAR ↗
15 May 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportSEC ↗
14 May 202610-QRevenue $648M (+16% y/y); Net income $42M (+702% y/y); Operating cash flow $4Mopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$648M+16% y/y
Net income · Q1-2026$42M+702% y/y
Operating cash flow · Q1-2026$4M
Cash and cash equivalents · 2026-04-04$189M
Gross margin · Q1-2026$205M+12% y/y
PDS Revenue · Private Duty Services · Q1-2026$536M+16% y/y
HHH Revenue · Home Health & Hospice · Q1-2026$67M+17% y/y
MS Revenue · Medical Solutions · Q1-2026$46M+7% y/y
Acquisition-related costs · Q1-2026$3M

Risks flagged

Regulatory investigation risk

“The Company has received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, requiring production of documents pertaining to nurse wages, reimbursement rates, and hiring activities.” · word for word

Medicaid reimbursement risk

“Changes to Medicaid to be implemented under the One Big Beautiful Bill Act could impact funding and reimbursement rates.” · word for word

Labor cost pressure

“Shortages in qualified employees and management and competition for qualified personnel.” · word for word

High leverage risk

“Total long-term obligations of $1,297.2 million net of unamortized debt issuance costs as of April 4, 2026.”
Read the original on SEC EDGAR ↗
14 May 20268-K · 2.02, 7.01Revenue $648M (+16% y/y); Net income $42M (+702% y/y); Adjusted EBITDA $84M (+25% y/y); Guidance: Revenue guidance raised by $20M midpoint; Adj EBITDA guidance raised by $10M midpointearningsopen

Figures in the filing · each found in the filing text

Revenue · Q1-2026$648M+16% y/y
Net income · Q1-2026$42M+702% y/y
Adjusted EBITDA · Q1-2026$84M+25% y/y
Revenue guidance (FY2026) · FY2026$2.57B

Guidance

Revenue guidance raised by $20M midpoint; Adj EBITDA guidance raised by $10M midpoint

Raised FY2026 revenue and adjusted EBITDA guidance reflecting strong Q1 performance and positive momentum.

Risks flagged

Regulatory approval dependency for Family First Homecare transaction may delay expected synergies.

“While we finalize the regulatory approval process on the Family First Homecare transaction” · word for word
Read the original on SEC EDGAR ↗
17 Apr 2026DEF 14ARevenue $2.43B (+20% y/y); Adjusted EBITDA $321M (+75% y/y); Operating cash flow $126Mopen

Figures in the filing · each found in the filing text

Revenue · FY2025$2.43B+20% y/y
Adjusted EBITDA · FY2025$321M+75% y/y
Operating cash flow · FY2025$126M
Free cash flow · FY2025$131M
Net income · FY2025$225M

Risks flagged

Regulatory investigation risk

“The Company has received grand jury subpoenas from the U.S. Department of Justice, Antitrust Division, requiring production of documents pertaining to nurse wages, reimbursement rates, and hiring activities.”

Medicaid reimbursement risk

“Changes to Medicaid to be implemented under the One Big Beautiful Bill Act could impact funding and reimbursement rates.”

High leverage risk

“Total long-term obligations of $1,297.2 million net of unamortized debt issuance costs as of April 4, 2026.”

Labor cost pressure

“Shortages in qualified employees and management and competition for qualified personnel.”
Read the original on SEC EDGAR ↗
20 Mar 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportSEC ↗
19 Mar 202610-KRisks named: Medicare Reimbursement Rate Cut, Medicaid Funding Cuts, Labor Cost Inflation, Managed Care Rate Pressureopen

Risks flagged

Medicare Reimbursement Rate Cut

“On November 28, 2025, CMS released a final rule for fiscal year 2026 that cuts Medicare reimbursement rates by 1.3%.” · word for word

Medicaid Funding Cuts

“The OBBBA includes, among other provisions, certain funding cuts to the Medicaid program, such as a reduction of funding for states choosing to expand the state’s Medicaid program, and updated eligibility requirements for Medicaid beneficiaries.” · word for word

Labor Cost Inflation

“In recent years, the labor markets have been challenging as a result of both shortages in workforce and inflationary wage pressures, which have constrained our ability to recruit and retain caregivers to meet patient demand.” · word for word

Managed Care Rate Pressure

“Managed care organizations, such as health maintenance organizations (HMOs) and preferred provider organizations (PPOs), and other third-party payers continue to consolidate, which enhances their ability to influence the delivery of healthcare services.” · word for word

Cybersecurity Breach

“We, our patients, and our third-party service providers have been the victims of these types of threats, attacks and security breaches in the past.” · word for word
Read the original on SEC EDGAR ↗
19 Mar 20268-K · 2.02, 7.01Revenue $662M (+27% y/y); Net income $179M (+512% y/y); Adjusted EBITDA $85M (+54% y/y); Guidance: Revenue $2.54-$2.56B; Adjusted EBITDA $318-$322Mearningsopen

Figures in the filing · each found in the filing text

Revenue · Q4-2025$663M+27% y/y
Net income · Q4-2025$179M+512% y/y
Adjusted EBITDA · Q4-2025$85M+54% y/y
Gross margin · Q4-202532.2%
Net income per diluted share · Q4-2025$0.80+471% y/y
Adjusted net income per diluted share · Q4-2025$0.17+240% y/y
Revenue (Full Year) · FY2025$2.43B+20% y/y

Guidance

Revenue $2.54-$2.56B; Adjusted EBITDA $318-$322M

Maintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion; Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million

Risks flagged

Gross margin slightly declined from 33.0% to 32.2% YoY, indicating potential cost pressure.

“Gross margin was $213.3 million, or 32.2% of revenue, for the three-month period ended January 3, 2026, as compared to $171.7 million, or 33.0% of revenue, for the three-month period ended December 28, 2024” · word for word
Read the original on SEC EDGAR ↗
12 Mar 20268-K · 8.01Cash purchase price $176Mopen

Figures in the filing · each found in the filing text

cash purchase price · Q2-2026$176M

Risks flagged

Antitrust review and customary closing conditions may delay or prevent closing.

“Transaction subject to HSR Act waiting period and absence of any law or order preventing the transaction.”
Read the original on SEC EDGAR ↗
27 Feb 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open

Risks flagged

Board composition change may signal governance transition, but no disagreement indicates low risk.

“Resignation not due to disagreement; no other material changes disclosed.”
Read the original on SEC EDGAR ↗
20 Feb 20268-K · 5.02CEO annual base salary $750,000.00; CFO annual base salary $500,000.00; CLO annual base salary $450,000.00open

Figures in the filing · each found in the filing text

CEO annual base salary · FY2026$750000.00
CFO annual base salary · FY2026$500000.00
CLO annual base salary · FY2026$450000.00

Risks flagged

Generous severance and change-in-control benefits could create retention costs or misalignment.

“CEO severance of 2x salary plus bonus outside CIC, 2.5x inside CIC; similar for other NEOs.”
Read the original on SEC EDGAR ↗
14 Jan 20268-K · 2.02, 7.01Revenue $2.44B; revenue guidance $2.55B; Guidance: FY2025 revenue raised to $2.425-2.445B from >$2.375B; Adj. EBITDA raised to $318-322M from >$300Mearningsopen

Figures in the filing · each found in the filing text

revenue · FY2025$2.44B
revenue guidance · FY2026$2.55B

Guidance

FY2025 revenue raised to $2.425-2.445B from >$2.375B; Adj. EBITDA raised to $318-322M from >$300M

Raised FY2025 guidance on both revenue and Adjusted EBITDA; initial FY2026 guidance implies continued growth.

Risks flagged

Preliminary results subject to audit adjustments; reliance on reimbursement rates.

“Financial statements not yet available; preliminary estimates subject to change.”
Read the original on SEC EDGAR ↗
14 Nov 20258-K · 1.01, 5.02Entered a material definitive agreement (acquisition, partnership, or major contract); reported the departure of a director or principal officer (CEO/CFO change)open

Risks flagged

Governance changes; executive share transfer restrictions may impact liquidity.

“certain executives may only sell, transfer, assign, pledge or otherwise directly or indirectly dispose of shares of Common Stock to the extent that such Transfer is pre-approved by the Compensation Committee”
Read the original on SEC EDGAR ↗
7 Nov 20258-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportSEC ↗
6 Nov 202510-QAveanna reported strong Q3 2025 results with 22.2% revenue growth and turned profitable, driven by Private Duty Services segmentearningsopen

Figures in the filing · each found in the filing text

Revenue · Consolidated · Q3-2025$622M+22% y/y
Gross Margin · Consolidated · Q3-202532.6%
Net Income · Consolidated · Q3-2025$14M
PDS Revenue · Private Duty Services · Q3-2025$514M+26% y/y
HHH Revenue · Home Health & Hospice · Q3-2025$62M+15% y/y
MS Revenue · Medical Solutions · Q3-2025$45M-1% y/y

Risks flagged

Legal and regulatory investigations

“The Company is fully cooperating with the Antitrust Division with respect to this investigation, and management believes that a loss event is not probable.” · word for word

Insurance reserve exposure

“Insurance reserves totaling $90.2 million were included on the interim unaudited consolidated balance sheets”
Read the original on SEC EDGAR ↗
6 Nov 20258-K · 2.02, 7.01Revenue $622M (+22% y/y); Gross margin $203M (+27% y/y); Net income $14M; Guidance: FY2025 revenue >$2.375B (from >$2.3B); Adjusted EBITDA >$300M (from >$270M)earningsopen

Figures in the filing · each found in the filing text

Revenue · total · Q3-2025$622M+22% y/y
Gross margin · total · Q3-2025$203M+27% y/y
Net income · total · Q3-2025$14M
Adjusted EBITDA · total · Q3-2025$80M+68% y/y
Revenue · total · 9M-2025$1.77B+18% y/y
Gross margin · total · 9M-2025$597M+29% y/y
Net income · total · 9M-2025$46M
Adjusted EBITDA · total · 9M-2025$236M+84% y/y
Cash and cash equivalents · total · Q3-2025$146M
Free cash flow · total · 9M-2025$86M

Guidance

FY2025 revenue >$2.375B (from >$2.3B); Adjusted EBITDA >$300M (from >$270M)

Raised full-year guidance on both revenue and Adjusted EBITDA, reflecting strong operational momentum and successful integration.

Risks flagged

High leverage with total debt of $1.49B; interest rate exposure partially hedged.

“Total indebtedness of $1,490.0 million; interest rate swaps and caps in place.” · word for word

Integration risk from Thrive Skilled Pediatric Care acquisition.

“Integration of Thrive Skilled Pediatric Care is on track to be completed by the end of the year.” · word for word
Read the original on SEC EDGAR ↗

Aveanna Healthcare Holdings Inc. — questions

What did Aveanna Healthcare Holdings Inc. file recently?
23 SEC filings in the last 12 months. Latest: 8-K on 2026-10-02 — Director Steven E. Rodgers resigned from the Board effective immediately, with no disagreement with the company. Independent director on Audit and Compensation Committees.

Every figure on this page comes from Aveanna Healthcare Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.